- Poster presentation
- Open Access
A case of sitosterolaemia with stomatocyticanaemia and thrombocytopenia treated with Ezetimibe with good response
International Journal of Pediatric Endocrinologyvolume 2013, Article number: P174 (2013)
Sitosterolaemia is a rare autosomal recessive lipid disorder characterized by increased absorption of plant sterols in the gut and decreased biliary excretion of sterols causing accumulation of plasma sterols, which can lead to premature atherosclerosis.
Here we reported a boy presented with multiple tuberous xanthomas at 4 year sold and was diagnosed sitosterolaemia . The fasting plasma total cholesterol and low-density lipoprotein (LDL) cholesterol levels were 18.3 mmol/L and 16.41 mmol/L respectively. Gas chromatography and mass spectrometry showed thatthefasting plasma sterols contained elevated beta-sitosterol 880 µmol/L (Reference range<12 µmol/L), campesterol489 µmol/L (Reference range <17.5 µmol/L) and stigmasterol38.9 µmol/L (Reference range <3.5 µmol/L).Molecular study identified compound heterozygous mutations (R419H and IVS12+IG→A)in the adenosine triphosphate (ATP) binding cassette subfamily G, member 5 (ABCG5) gene.
Initial management included dietary restriction in cholesterol and plant sterols and cholestyraminetreatment.The total cholesterol and LDL cholesterol levels decreased.
The boy developed bleeding tendency with gum bleeding and epistaxis and hepatosplenomegalyat 7 years old. Blood test confirmed and thrombocytopenia and peripheralsmear revealed stomatocytichaemolyticanaemia and giant platelets . Bone marrow study showed hypercellular marrow. He was treated with increasing dose of cholestyraminebut the drug compliance was fair.The haematological problems persisted.
At the age of 13,Ezetimibe 10mg daily was added. Ezetimibe blocks the absorption of dietary and biliary sources of cholesterol and plant sterols. The platelet count rose from 58 x 109/L to 107 x 109/L in 4 weeks’ time and normalized after 10 months of Ezetimibe treatment. The haemoglobin level rose from 11 g/dL to 13.8 g/dL in 4 months. The plant sterol level also showed significant improvement (see table 1). There were decreased liver and spleen size. The drug was well tolerated with no adverse effect. The efficacy of Ezetimibe in our patient was sustained after 4 years of treatment which was consistent with the other studies on long-term Ezetimibe treatment [3–6].
In conclusion, Ezetimibe treatment was effective in lowering the plasma cholesterol and sterols level in our patient with sitosterolaemia. It is also effective in reversing the stomatolyticanaemia and thrombocytopenia.
Cheng WF, Yuen YP, et al: Sitosterolaemia and xanthomatosis in a child. Hong Kong Med J. 2003, 9: 206-209.
Rees DC, Iolascon A, et al: Stomatocytichaemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/ macrothrombocytopenia) is the haematological presentation of phytosterolaemia. British Journal of Haematology. 2005, 130: 297-309. 10.1111/j.1365-2141.2005.05599.x.
Salen G, von Bergmann K, et al: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004, 109: 966-971. 10.1161/01.CIR.0000116766.31036.03.
Salen G, Starc T, et al: Intestinal cholesterol absorption inhibitor Ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology. 2006, 130: 1853-1857. 10.1053/j.gastro.2006.02.027.
Lutjohann D, von Bergmann K, et al: Long-term efficacy and safety of ezetimibe 10mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Int J ClinPract. 2008, 62: 1499-1510.
Niu DM, Chong KW, et al: Clinical observations, molecular genetic analysis, and treatment of sitosterolemia in infants and children. J Inherit Metab Dis. 2010, 33: 437-443. 10.1007/s10545-010-9126-2.